PSH

• In the Americas, the trend is toward eco-friendly and cost-efficient energy solutions, supported by incentives encouraging micro hydropower systems adoption.
• Micro hydropower stands at the forefront of the shift toward sustainable development, offering a reliable, renewable, and community-focused energy solution.
• We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Micro Hydropower Market.
• "Dive into the Micro Hydropower Market Landscape: Explore 184 Pages of Insights, 296 Tables, and 22 Figures"

• LONDON, Ontario and WINDHAM COUNTY, Conn., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced the U.S. Food and Drug Administration (FDA) has granted both Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) for the company’s Hemophilia A program.
• The FDA grants orphan designation, also referred to as orphan status, to therapies intended for the treatment of rare diseases that affect fewer than 200,000 people in the U.S.
• This designation provides certain benefits, including tax credits for qualified clinical testing, waiver or partial payment of FDA application fees and seven years of market exclusivity, if approved.
• Separately, rare pediatric disease designations are granted for rare diseases that primarily affect children under 18 years old with recipients of this designation being awarded a priority review voucher, upon approval.

Any person wishing to attend must be an existing PSH shareholder or bondholder at the time of the presentation. A livestream of the event will also be available. Additional eligibility and registration details are available at www.pershingsquareholdings.com .

• The following summarizes key advancements presented:
  The final conformal coating composition exhibits significantly improved cell compatibility and overall biocompatibility, representing evolution across years of process development work and preclinical testing.
• The final conformal coated product was purified using a process to contain 98% conformal coated islets and only 2% empty capsules.
• “We have made significant advancements in the evolution of the conformal coating technology in our collaboration with Sernova and are confident we have the final formulation.
• “Our goal is to continue to drive this technology ahead and ultimately bring a local immune-protected cell product into the clinic combined with the Sernova Cell Pouch and iPSC islet-like clusters.”